血液病的细胞因子治疗被引量：2

下载PDF

导出

摘要血液病的细胞因子治疗同济医科大学附属同济医院李守新，刘文励，武汉４３００３０细胞因子是由免疫细胞或非免疫细胞分泌的小分子多肽，它作用于造血细胞增殖分化、发育的各个阶段，具有多方面造血调控作用。得益于基础研究和基因工程的飞跃发展，细胞因子的克隆、重组和...

作者李守新刘文励

机构地区同济医科大学附属同济医院

出处《内科急危重症杂志》 1996年第3期133-135,共3页 Journal of Critical Care In Internal Medicine

关键词血液病细胞因子药物疗法

同被引文献24

1Oster W,Hermann F,Gann H,et al.Erythropoietin for the treatment of anemia of malignancy associated with neoplastia bone marrow infiltration[J].J Clin Oncol,1990,8(6):956.
2Kasper C,Terhaar A,Fossa A,et al.Recombinant human erytbropoietin in the treatment of cancer-related anaemis[J].Eur J Haematol,1997,58(4):251.
3Seidenfeld J,Piper M,Flamm C,et al.Epoetin treatment of anemia associated with cancer therapy:a systematic review and meta-analyais of controlled clinical trials[J].J Natl Cancer Inst,2001,93(16):1204.
4Beguin Y.Erythropoietin and the anemia of cancer[J].Acta Clin Belg,1996,51(1):36-52.
5Gary Walsh. Biopharmaceuticals: Biochemistry and biotechnology[M]. Second Edition(2003). John Wiley & Sons Ltd, ISBN0-470-84326-8.
6Walsh, G. Biopharmaceutic benchmarks-2003[J]. Nat. Biotechnol. 2003; 2l(2):870-878.
7Bibby, K., Davis, J., Jones, C.Biopharmaceuticals - Moving to Centre Stage[M].BioPeople North, American Biotechnology Industry and Suppliers' Guide.2003:3-11.
8Beijing Pharma and Biotech Center, Annual report for development of Beijing Pharma & Biotech industry: 2005[R]. China Science Press,2005:78-106.
9Hu, X. W., Ma, Q. J., Zhang, S. Y. Biopharmaceuticals in China[J]. Biotechnol,2006,1:12 I5 - 1224.
10Schofleld J. R., Robinson W.A., Murphy J. R., et al. Low doses of Interferon-or are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia[J]. Ann Inter Med, 1994,121(10):736-743.

内科急危重症杂志

1996年第3期

内容加载中请稍等...